The Breast Biopsy Market is increasingly driven by the integration of imaging guidance technologies such as ultrasound, stereotactic systems, MRI, and CT. MRFR reports that ultrasound-guided biopsies remain the most widely adopted method owing to real-time visualization, affordability, and lack of radiation exposure. Stereotactic guidance is especially useful for mammographic findings, while MRI guidance is essential when lesions are only detectable via MRI. These technologies are critical in ensuring precise targeting of lesions—particularly small or non-palpable ones—thus improving diagnostic outcomes and minimizing patient distress. As imaging integration becomes standard, procedure volumes are rising and clinical confidence continues to grow.